Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTC-S1
- Development stage
- Preclinical
- Lead developer
- Biotts
- Modality
- Peptides
- Administration
- Transdermal
01
Overview
MTC-S1 is a transdermal patch formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, being developed by Biotts for the treatment of type 2 diabetes. The drug utilizes Biotts' proprietary Multicomponent Transport System (MTC) technology, which facilitates the delivery of large therapeutic molecules across the skin barrier. This approach is intended to offer a painless, non-invasive alternative to traditional subcutaneous injections, potentially improving patient adherence and providing more stable plasma concentrations of the drug. MTC-S1 is currently in the preclinical stage of development.
- Other names
- semaglutide transdermal patch
02
Targets
Beyond the preview
Go deeper on MTC-S1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MTC-S1.